Thesis icon

Thesis

Assessing the role of ADAM10 in Trastuzumab treatment and resistance

Abstract:

Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback for the drug. Understanding the mechanisms behind Herceptin resistance is crucial in order to increase the efficacy of the treatment. Many factors have been shown to contribute to resistance, including ...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Oxford college:
Balliol College
Role:
Author

Contributors

Division:
MSD
Department:
Oncology
Role:
Supervisor
Publication date:
2012
Type of award:
MSc by Research
Level of award:
Masters
Awarding institution:
Oxford University, UK
Language:
English
Keywords:
Subjects:
UUID:
uuid:56207cef-a8c1-468f-899b-48001c51a1c0
Local pid:
ora:7165
Deposit date:
2013-08-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP